Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inverness’ $92.5 Mil. Abbott Rapid Testing Buy Could Return TestPack To U.S.

This article was originally published in The Gray Sheet

Executive Summary

Abbott Labs will retain exclusive distribution rights for the TestPack and Signify test lines in the U.S., while the products' new owner - Inverness Medical Innovations - will take on international distribution responsibilities

You may also be interested in...



Inverness Medical Innovations

$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...

Inverness Medical Innovations

$56.5 mil. purchase of Abbott Laboratories' Determine and DainaScreen rapid infectious disease diagnostics will provide the Waltham, Mass. firm with a "viable platform" to "solidify our commitment to the Japanese market," Inverness CEO Ron Zwanziger explains May 31. Inverness previously purchased pregnancy, strep throat, and drugs-of-abuse rapid diagnostic test lines from Abbott for international distribution (1"The Gray Sheet" Oct. 6, 2003, p. 20). Determine/DainaScreen generated roughly $23 mil. for Abbott in 2004...

Inverness Will Develop Home-Use Heart Test At Scottish R&D Facility

ITI Life Sciences, a Scottish economic and business development initiative, will provide Inverness Medical Innovations with $57 mil. through 2008 to help identify novel biomarkers for near-patient and home-use cardiovascular disease tests

Related Content

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel